PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC FAT HEPATOSIS AND METHOD FOR PREVENTING OR TREATMENT OF NON-ALCOHOLIC FATTY HEPATOSIS USING IT
1. A pharmaceutical composition for the prevention or treatment of non-alcoholic fatty hepatosis, comprising an active ingredient selected from the group consisting of compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or their pharmaceutically acceptable salts [Formula 1] 2. The composition of claim 1, wherein the active ingredient is compound 1 represented by formula 1, or a pharmaceutically acceptable salt thereof. The composition of claim 2, wherein the active ingredient is tartrate of compound 1.4. The composition of claim 1, wherein the active ingredient is sitagliptin or a pharmaceutically acceptable salt thereof. The composition of claim 4, wherein the active ingredient is sitagliptin phosphate. The composition of claim 1, wherein the active ingredient is vildagliptin or a pharmaceutically acceptable salt thereof. The composition of claim 1, wherein the active ingredient is linagliptin or a pharmaceutically acceptable salt thereof. A composition according to any one of claims 1 to 7, wherein non-alcoholic fatty hepatosis occurs as a result of hyperlipidemia, diabetes or obesity. A composition according to any one of claims 1 to 7, wherein the non-alcoholic fatty hepatosis is selected from the group consisting of simple steatosis, non-alcoholic steatohepatitis, liver fibrosis and cirrhosis of the liver. A method for preventing or treating non-alcoholic fatty hepatosis, comprising administering an effective amount of an active ingredient selected from the group consisting of compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or their pharmaceutically acceptable salts to a mammal, including a person in need thereof [Formula 1] eleven. The method of claim 10, wherein the active ingredient is1. Фармацевтическая композиция для предупреждения или лечения неалкогольного жирового гепатоза, включающая активный ингредиент, выбираемый из группы, состоящей из соединения 1 представленного формулой 1, ситаглиптина, вилдагли
